PDGFRA and neoplasm: Assessment of somatic copy number variants (focal homozygous deletions or ≥2-copy gain somatic copy number variants using a Log2 fold change of ≤−0.9 and ≥0.4) from the 24 WGS tumor/normal pairs (Figs. 2, 3c, Supplementary Data 7) revealed focal copy number gains in CFA 13 involving PDGFRA (29% WGS) and MYC (38% WGS).